Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Obatoclax may stop the growth of chronic lymphocytic leukemia by blocking blood flow to the
cancer and by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as fludarabine, work in different ways to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as
rituximab, can block cancer growth in different ways. Some block the ability of cancer cells
to grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them. Giving obatoclax together with fludarabine and rituximab may kill more
cancer cells. This phase I trial is studying the side effects and best dose of obatoclax when
given together with fludarabine and rituximab in treating patients with B-cell chronic
lymphocytic leukemia.